Ipilimumab
Neuroendocrine Neoplasm
Olivia Newton-John Cancer Research Institutemonoclonal_antibodyPhase 2Active
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
58 Active assets in the Neuroendocrine Neoplasm cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Eloxatin ITM Solucin GmbH | Phase 3 | BB |
FLUOROURACILUM ITM Solucin GmbH | Phase 3 | BB |
Bms-907351 Fox Chase Cancer Center | Phase 3 | BB |
Irinotecan First Affiliated Hospital Xi'an Jiaotong University | Phase 4 | BB |
Everolimus Exelixis | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Ipilimumab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →